Axial Disease in Psoriatic Arthritis

Disclosures

Dr. Helliwell has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, Pfizer and Janssen.

References

1. Wright V, Moll JMH. Seronegative Polyarthritis. Amsterdam: North Holland Publishing Co. 1976.
2. Chandran V, Barrett J, Schentag CT, et al. Axial psoriatic arthritis: Update on a longterm prospective study. J Rheumatol. 2009 Dec;36(12):2744–2750.
3. Chandran V, Tolusso DC, Cook RJ, Gladman DD. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. J Rheumatol. 2010 Apr;37(4):809–815.
4. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheum Dis. 1998 Mar;57(3):135–140.
5. Feld J, Ye JY, Chandran V, et al. Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology (Oxford). 2020 Jun 1;59(6):1340–1346.
6. Eder L, Chandran V, Pellet F, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2012 Jan;71(1):50–55.
7. Coates LC, Baraliakos X, Blanco FJ, et al. The phenotype of axial spondyloarthritis: Is it dependent on HLA-B27 status? Arthritis Care Res (Hoboken). 2021 Jun;73(6):856-860.
8. Jadon DR, Sengupta R, Nightingale A, et al. Axial disease in psoriatic arthritis study: Defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2017 Apr;76(4):701–707.
9. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777–783.
10. Coates LC, Soriano E, Corp N, et al. OP0229 The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations 2021. Ann Rheum Dis. 2021;80(Suppl 1):139–140.
11. Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019 Feb;71(2):258–270.
12. Baeten D, Østergaard M, Wei JCC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebocontrolled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295–1302.
13. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: Results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021 May;80(5):582–590.
14. Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: A post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021 Oct 1;3(10):e715–e723.
15. Helliwell PS, Gladman DD, Chakravarty SD, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFinaïve active psoriatic arthritis patients with physician-reported spondylitis: Pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020 Feb;6(1) e001149.
16. Reddy S, Husni M, Scher J, et al. Use of the BASDAI in psoriatic arthritis patients with and without axial disease. Meeting Abstract. ACR Convergence 2020. Abstract 0344. 2020 Nov 5–9.
17. Poddubnyy D, Baraliakos X, Van den Bosch F, et al. Axial involvement in psoriatic arthritis cohort (AXIS): The protocol of a joint project of the Assessment of SpondyloArthritis International Society (ASAS) and theGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ther Adv Musculoskelet Dis. 2021 Dec 18;13:1759720×211057975.
18. Poddubnyy D, Mease PJ, Van den Bosch F, et al. AB0824 Which parameters are relevant in the identifying axial involvement in psoriatic arthritis?—Results of a survey among ASAS and GRAPPA members. Ann Rheum Dis. 2020;79(Suppl1):1715–1716.